Recent advances in large-scale production of monoclonal antibodies and related proteins

Trends in Biotechnology

Volumn 28, Issue 5, 2010, Pages 253-261

  Shukla, Abhinav A ^a   Thömmes, Jörg ^b  

^a BRISTOL MYERS SQUIBB COMPANY   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPROCESS DEVELOPMENT; CHROMATOGRAPHIC SEPARATIONS; DOWNSTREAM PROCESS; INDUSTRIAL PRODUCTION; LARGE-SCALE PRODUCTION; MAMMALIAN CELL CULTURE; MANUFACTURING PROCESS; PLATFORM APPROACH; RAPID DEVELOPMENT; RELATED PRODUCTS;

ANIMAL CELL CULTURE; LIQUID CHROMATOGRAPHY; MAMMALS; MONOCLONAL ANTIBODIES; PRODUCTION ENGINEERING; SURFACE PLASMON RESONANCE;

CELL CULTURE;

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RILONACEPT; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

BIOTECHNOLOGICAL PROCEDURES; BIOTECHNOLOGICAL PRODUCTION; CHROMATOGRAPHY; DRUG IMPURITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PURIFICATION; LARGE SCALE PRODUCTION; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; ULTRAFILTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL CULTURE TECHNIQUES; CHROMATOGRAPHY; DRUG INDUSTRY; HUMANS; PROTEINS;

MAMMALIA;

EID: 77951979046     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.02.001     Document Type: Review

References (79)

1. Reichert J., Valge-Archer V. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 2007, 6:349-356.
2. Carter P. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
3. Ruuls S., et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol. J. 2008, 3:1157-1171.
4. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nature 2009, 8:226-234.
5. Weiner L. Fully human therapeutic monoclonal antibodies J. Immunotherapy 2006, 29:1-9.
6. Shukla A., et al. Downstream processing of monoclonal antibodies - application of platform approaches. J. Chromatogr. B 2007, 848:28-39.
7. Kelley B. Very large-scale monoclonal antibody purification - the case for conventional unit operations. Biotechnol. Prog. 2007, 23:995-1008.
8. Kelley B. Industrialization of mAb production technology - the bioprocessing industry at a crossroads. MAbs 2009, 1:1-10.
9. Birch J., Racher A. Antibody production. Adv. Drug Deliv. Rev. 2006, 58:671-685.
10. Chusainow J., et al. A study of monoclonal antibody producing CHO cell lines - what makes a stable high producer?. Biotechnol. Bioeng. 2009, 102:1182-1196.
11. Jiang Z., et al. Regulation of recombinant monoclonal antibody production in CHO cells - a comparative study of gene copy number, mRNA level and protein expression. Biotechnol. Progr. 2006, 22:313-318.
12. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22:1393-1398.
13. Chu L., Robinson D. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 2001, 12:180-187.
14. Wagner-Rousset E., et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level MS based strategies J. Chromatogr. B 2008, 872:23-37.
15. Majors B., et al. Mcl-1 overexpression leads to higher viabilities and increased production of humanized monoclonal antibody in CHO cells. Biotechnol. Progr. 2009, 25:1161-1168.
16. Jain E., Kumar A. Upstream processes in antibody production - evaluation of critical parameters. Biotechnol. Adv. 2008, 26:46-72.
17. Lee C., et al. A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol. Bioeng. 2008, 102:1107-1118.
18. Haldankar R., et al. Serum free suspension large-scale transient tranfection of CHO cells in WAVE bioreactors. Mol. Biotechnol. 2006, 34:191-199.
19. Ye J., et al. High-level protein expression in scaleable CHO transient transfection. Biotechnol. Bioeng. 2009, 103:542-551.
20. Crowell C., et al. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol. Bioeng. 2007, 96:538-549.
21. Wong D., et al. Impact of dynamic on-line fed-batch strategies on metabolism, productivity and N-glycosylation in CHO cell cultures. Biotechnol. Bioeng. 2004, 89:164-177.
22. Matsunaga N., et al. Estimation of dissolved carbon dioxide stripping in a large bioreactor using model medium. J. Biosci. Bioeng. 2009, 107:49-424.
23. Roopenian D., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:715-725.
24. Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 2006, 24:1241-1252.
25. Hossler P., et al. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009, 19:936-949.
26. Shukla A., Kandula J. Harvest and recovery of monoclonal antibodies from large-scale mammalian cell culture. Biopharm. Int. 2008, 7:34-45.
27. Yigzaw Y., et al. Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnol. Progr. 2006, 22:288-296.
28. Kozlowski S., Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv. Drug Deliv. Rev. 2006, 58:707-722.
29. Low D., et al. Future of antibody purification. J. Chromatogr. B 2007, 848:48-63.
30. Ghose S., et al. Integrated polishing steps for monoclonal antibody production. Process Scale Purification of Antibodies 2009, 145-167. Wiley. 1st edn. U. Gottschalk (Ed.).
31. Follman D., Fahrner R. J. Chromatogr. A 2004, 1024:79-85.
32. Arunakumari A., Wang J. Purification of human monoclonal antibodies - non Protein A strategies. Process Scale Purification of Antibodies 2009, 103-123. Wiley. 1st edn. U. Gottschalk (Ed.).
33. Ghose S., et al. Protein interactions in hydrophobic charge induction chromatography (HCIC). Biotechnol. Progr. 2005, 21:498-508.
34. Ghose S., et al. Evaluation and comparison of alternatives to Protein A chromatography - mimetic and hydrophobic charge induction chromatographic stationary phases. J. Chromatogr. A 2006, 1122:144-152.
35. Liu J., et al. Comparison of camelid antibody ligand to Protein A for monoclonal antibody purification. Biopharm. Int. 2009, 22:35-43.
36. Zandian M., Jungbauer A. Engineering properties of a camelid antibody affinity sorbent for immunoglobulin G purification. J. Chromatogr. A 2009, 1216:5548-5556.
37. Ghose S., et al. Antibody variable region interactions with Protein A - implications for the development of generic purification processes. Biotechnol. Bioeng. 2005, 92:665-673.
38. Ghose S., et al. Binding capacity differences for antibodies and Fc-fusion proteins on Protein A chromatographic materials. Biotechnol. Bioeng. 2007, 96:768-779.
39. Tugcu N., et al. Maximizing productivity of chromatographic steps for purification of monoclonal antibodies. Biotechnol. Bioeng. 2008, 99:599-613.
40. Ghose S., et al. Use and optimization of a dual flow-rate loading strategy for maximizing throughput in Protein A affinity chromatography. Biotechnol. Progr. 2004, 20:830-840.
41. Jiang C., et al. A mechanistic study of Protein A chromatography resin lifetime. J. Chromatogr. A 2009, 1216:5849-5855.
42. Rogers M., et al. Development of a rapid sanitization solution for silica-based protein A affinity adsorbents. J. Chromatogr. A 2009, 1216:4589-4596.
43. Brorson K., et al. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A 2003, 989:155-163.
44. Shukla A., Hinckley P. Host cell protein clearance during Protein A chromatography - development of an improved wash step. Biotechnol. Progr. 2008, 24:1115-1121.
45. Jin M., et al. Profiling of host cell proteins by two dimensional difference gel electrophoresis (2D-DIGE) - implications for downstream process development. Biotechnol. Bioeng. 2010, 105:306-316.
46. Shukla A., et al. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes. Biotechnol. Progr. 2008, 24:615-622.
47. Shukla A., et al. Protein aggregation kinetics during Protein A chromatography - case study for an Fc fusion protein. J. Chromatogr. A 2007, 1171:22-28.
48. Kandula S., et al. Design of a filter train for precipitate removal in mAb downstream processing. Biotechnol. Appl. Biochem. 2009, 54:149-155.
49. Gagnon P. IgG aggregate removal by charged hydrophobic mixed-mode chromatography. Curr. Pharm. Biotech. 2009, 10:434-439.
50. Zhao G., et al. Ligands for mixed-mode protein chromatography: principles, characteristics and design. J. Biotechnol. 2009, 144:3-11.
51. Zydney A., et al. Modeling electrostatic exclusion effects during ion exchange chromatography of monoclonal antibodies. Biotechnol. Bioeng. 2009, 102:1131-1140.
52. Kelley B., et al. Weak partitioning chromatography for anion-exchange purification of monoclonal antibodies. Biotechnol. Bioeng. 2008, 101:553-566.
53. Zhou J. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing. Biotechnol. Bioeng. 2008, 100:488-496.
54. Kern G., Krishnan M. Virus removal by filtration - points to consider. Biopharm. Int. 2006, 19:32-41.
55. Bohonak D., Zydney A. Compaction and permeability effects with virus filtration membranes. J. Membrane Sci. 2005, 254:71-79.
56. Ireland T., et al. Optimizing virus filtration performance with prefiltration. Bioprocess Intl. Supplement 2005, 3:44-47.
57. Marques B., et al. Virus filtration of high-concentration monoclonal antibody solutions. Biotechnol. Progr. 2009, 25:483-491.
58. Harris R., et al. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev. Res. 2004, 61:137-154.
59. Bee J., et al. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol. Bioeng. 2009, 103:936-943.
60. Bee J., et al. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol. Bioeng. 2010, 105:121-129.
61. Singh S., et al. Large-scale freezing of biologics. Bioprocess Intl. 2009, 7:32-44.
62. Przybycien T., et al. Alternative bioseparation operations - life beyond packed-bed chromatography. Curr. Opin. Biotech. 2004, 15:469-478.
63. Thommes J., Etzel M. Alternatives to chromatographic separations. Biotechnol. Progr. 2007, 23:42-45.
64. Grabowski H. Follow-on biologics - data exclusivity and the balance between innovation and competition. Nat. Rev. Drug. Discov. 2008, 7:478-488.
65. Azevedo A., et al. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol. 2009, 27:240-247.
66. Noel, R. (2007) Chromatography: industrial processing and biotherapeutics Filtration and Separation 44, 26-28.
67. Wang, J. et al. (2009) Precipitation of process-derived impurities in non-Protein A purification schemes for antibodies. Biopharm Intl. Special Issue on Downstream Processing 2010 - embracing innovation Oct, 4-10.
68. McDonald P., et al. Selective antibody precipitation using polyelectrolytes - a novel approach to the purification of monoclonal antibodies. Biotechnol. Bioeng. 2009, 102:1141-1151.
69. Azevedo A., et al. Affinity enhanced purification of human monoclonal antibodies by aqueous two-phase separation. Sepn. Purific. Technol. 2009, 65:31-39.
70. Ahamed T., et al. Phase behavior of an intact monoclonal antibody. Biophys. J. 2007, 93:610-619.
71. van Reis R., Zydney A. Bioprocess membrane technology. J. Membrane Sci. 2007, 302:16-50.
72. Rao S., Zydney A. High resolution protein separations using affinity ultrafiltration with small charged ligands. J. Membrane Sci. 2006, 280:781-789.
73. Zhou J., Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol. Progr. 2006, 22:341-349.
74. Chang C., et al. Advances and challenges in developing cytokine fusion proteins as improved therapeutics. Expert Opin. Drug. Discov. 2009, 4:181-194.
75. Deonarain M. Recombinant antibodies for cancer therapy. Expert Opin. Biol. Ther. 2008, 8:1123-1141.
76. Holliger P., Hudson P. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
77. Gill D., Damle N. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 2006, 17:653-658.
78. Dineen S., et al. The adnectin CT-322 is a novel VEGF receptor inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008, 8(352):1-10.
79. Andersen D., Reilly D. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15:456-462.